Evidence map›Paper›PMID 28668521›Full record

ReviewTranslational research : the journal of laboratory and clinical medicine2017

Lipidomics in translational research and the clinical significance of lipid-based biomarkers.

Daniel J Stephenson, L Alexis Hoeferlin, Charles E Chalfant

Open access · greenAbstract readReview
In one paragraph

Review in Translational research : the journal of laboratory and clinical medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 130 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Lipids: Driving Forces in the Underlying Biology of Carcinogenesis.ACS pharmacology & translational science · 2025
    Review
  7. Article
  8. PI3K Signaling at the Crossroads of Lipid Metabolism and Cancer.Advances in experimental medicine and biology · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Lipidomic signatures in patients with early-onset and late-onset Preeclampsia.Metabolomics : Official journal of the Metabolomic Society · 2024
    Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Daniel J StephensonDepartment of Biochemistry and Molecular Biology, Virginia Commonwealth University (VCU), Richmond, Va.
L Alexis HoeferlinDepartment of Biochemistry and Molecular Biology, Virginia Commonwealth University (VCU), Richmond, Va.
Charles E ChalfantDepartment of Biochemistry and Molecular Biology, Virginia Commonwealth University (VCU), Richmond, Va; Research Service, Hunter Holmes McGuire Veterans Administration Medical Center, Richmond, Va; VCU Massey Cancer Center, Cancer Cell Signaling Program, Virginia Commonwealth University, Richmond, Va; VCU Institute of Molecular Medicine, Richmond, Va; VCU Johnson Center for Critical Care and Pulmonary Research, Richmond, Va. Electronic address: charles.chalfant@vcuhealth.org.
Virginia Commonwealth University · USHunter Holmes McGuire VA Medical Center · US

Funding

Virus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Renato Martins · 1985 to 2026
$51.0M
The utilization of photonics technology to rapidly detect bioactive lipids associated with preeclampsia developmentU01HD087198 · NICHD · VIRGINIA COMMONWEALTH UNIVERSITY · PI CHALFANT, CHARLES E., WALSH, SCOTT W · 2015 to 2015
$4.2M
The functional role of the cPLA2alpha/C1P interaction in sepsis resolutionR01HL125353 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · PI BROWN, RHODERICK E, CHALFANT, CHARLES E. · 2014 to 2018
$4.0M
CONSTRUCTION OF SIGNALLING FACILITYC06RR017393 · NCRR · VIRGINIA COMMONWEALTH UNIVERSITY · PI TORR, MARSHA R · 2002 to 2002
$2.0M
AB SCIEX 5500 QTRAP Mass Spectrometer for Lipidomics and Metabolomics ResearchS10OD010641 · OD · VIRGINIA COMMONWEALTH UNIVERSITY · PI CHALFANT, CHARLES E. · 2012 to 2012
$578k
The role of the C1P/cPLA2alpha interaction in anaphylaxisR21AI109068 · NIAID · VIRGINIA COMMONWEALTH UNIVERSITY · PI CHALFANT, CHARLES E. · 2014 to 2015
$419k
The role of RNA splicing in non-small cell lung cancerI01BX001792 · VA · VA VETERANS ADMINISTRATION HOSPITAL · PI CHALFANT, CHARLES E. · 2013 to 2024
–
BLRD VA I01 BX001792NCI NIH HHS P30 CA016059NCRR NIH HHS C06 RR017393NHLBI NIH HHS R01 HL125353NIAID NIH HHS R21 AI109068NICHD NIH HHS U01 HD087198NIH HHS S10 OD010641
6 · The paper itself

Abstract

Lipidomics is a rapidly developing field of study that focuses on the identification and quantitation of various lipid species in the lipidome. Lipidomics has now emerged in the forefront of scientific research due to the importance of lipids in metabolism, cancer, and disease. Using both targeted and untargeted mass spectrometry as a tool for analysis, progress in the field has rapidly progressed in the last decade. Having the ability to assess these small molecules in vivo has led to better understanding of several lipid-driven mechanisms and the identification of lipid-based biomarkers in neurodegenerative disease, cancer, sepsis, wound healing, and pre-eclampsia. Biomarker identification and mechanistic understanding of specific lipid pathways linked to a disease's pathologies can form the foundation in the development of novel therapeutics in hopes of curing human disease.

Indexed as

MetabolomicsTranslational Research, BiomedicalBiomarkersDiseaseHumansLipidsMass SpectrometryBiomarkersLipids

Identifiers

PMID28668521
PMCPMC5659874
OpenAlexW2624697526

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.